These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 14603100)

  • 1. Mechanisms of lipid elevations associated with the treatment of patients with HIV infection.
    Piliero PJ
    MedGenMed; 2003 Jun; 5(2):1. PubMed ID: 14603100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for management and treatment of dyslipidemia in HIV/AIDS.
    Sax PE
    AIDS Care; 2006 Feb; 18(2):149-57. PubMed ID: 16338773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
    Calza L; Manfredi R; Chiodo F
    J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary heart disease risk, dyslipidemia, and management in HIV-infected persons.
    Fichtenbaum CJ
    HIV Clin Trials; 2004; 5(6):416-33. PubMed ID: 15682355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy.
    Senise JF; Castelo A; Martínez M
    AIDS Rev; 2011; 13(4):198-213. PubMed ID: 21975356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
    Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyslipidemia related to antiretroviral therapy.
    Estrada V; Portilla J
    AIDS Rev; 2011; 13(1):49-56. PubMed ID: 21412389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selected metabolic and morphologic complications associated with highly active antiretroviral therapy.
    Smith KY
    J Infect Dis; 2002 May; 185 Suppl 2():S123-7. PubMed ID: 12001033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001.
    Bonnet F; Balestre E; Thiébaut R; Mercié P; Dupon M; Morlat P; Dabis F;
    HIV Med; 2004 May; 5(3):133-9. PubMed ID: 15139977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risk among HIV-positive patients on antiretroviral therapy.
    Aberg JA
    J Int Assoc Physicians AIDS Care (Chic); 2003 Sep; 2 Suppl 2():S24-39. PubMed ID: 14569635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation and management of dyslipidemia in patients with HIV infection.
    Green ML
    J Gen Intern Med; 2002 Oct; 17(10):797-810. PubMed ID: 12390557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of dyslipidemia and other cardiovascular risk factors in HIV-infected patients: case-based review.
    Aberg JA
    Top HIV Med; 2006; 14(4):134-9. PubMed ID: 17114827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme.
    Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
    HIV Med; 2007 Mar; 8(2):80-5. PubMed ID: 17352763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lipodystrophy and lipid metabolism alterations in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].
    Calza L; Manfredi R; Chiodo F
    Recenti Prog Med; 2004 May; 95(5):265-75. PubMed ID: 15202680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of treatment-induced lipid abnormalities and lipodystrophy.
    Smith D
    J HIV Ther; 2001 May; 6(2):25-7. PubMed ID: 11501199
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular considerations in patients treated with HIV protease inhibitors.
    Colagreco JP
    J Assoc Nurses AIDS Care; 2004; 15(1):30-41. PubMed ID: 14983559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
    Martínez E; Tuset M; Milinkovic A; Miró JM; Gatell JM
    Antivir Ther; 2004 Oct; 9(5):649-63. PubMed ID: 15535403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
    Manfredi R; Chiodo F
    J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.